News

MTP Connect – Proteomics International signs deal with PrismHealthDx to launch PromarkerD predictive test for diabetic kidney disease in USA

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States, creating a partnership with US-based precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx).

Article: Proteomics International signs deal with PrismHealthDx to launch PromarkerD predictive test for diabetic kidney disease in USA

Subscribe
  • This field is for validation purposes and should be left unchanged.